Fragile X syndrome (FXS) is caused by loss of the fragile X mental retardation 1 gene product, a repressor of mRNA translation. It is thought that excessive protein synthesis downstream of metabotropic glutamate receptor 5 activation leads to many of the neuropsychiatric symptoms of FXS. The authors show that lovastatin, a widely prescribed cholesterol-lowering drug, can normalize protein synthesis in the hippocampus of a mouse model of FXS and prevent epileptogenesis. Although the effects of the drug on the neurocognitive phenotypes of these mice remain to be investigated, lovastatin could be a promising therapy for FXS.